Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25910696 | 0.78 | CYP11B1 (0.37) | TRPV4CYP11B1CYP11B2KHKDHODH | |
| SCHEMBL1996117 | 0.76 | TRPV4 (0.41) | TRPV4CYP11B1CYP11B2KHKDHODH | |
| SCHEMBL2234841 | 0.74 | TRPV4 (0.48) | TRPV4CYP11B1CYP11B2KHKDHODH | |
| SCHEMBL2929573 | 0.74 | CES2 (0.36) | — | |
| SCHEMBL2651893 | 0.73 | TRPV4 (0.39) | TRPV4CYP11B1CYP11B2KHKDHODH | |
| SCHEMBL2652439 | 0.73 | ADRB2 (0.44) | TRPV4CYP11B1CYP11B2KHKDHODH | |
| SCHEMBL29786557 | 0.73 | ERN1 (0.42) | TRPV4CYP11B1CYP11B2KHKDHODH | |
| SCHEMBL20597951 | 0.73 | KHK (0.41) | TRPV4CYP11B1CYP11B2KHKDHODH | |
| SCHEMBL4254090 | 0.73 | ERN1 (0.42) | TRPV4CYP11B1CYP11B2KHKDHODH | |
| SCHEMBL13525263 | 0.73 | DHODH (0.40) | TRPV4CYP11B1CYP11B2KHKDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| EP-2394987-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090304-A1 | ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | HTR5A, HTR2A, HTR1A | TRPV4 1593/4885CYP11B1 766/4885CYP11B2 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.